Charles L. Sawyers

Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center

Affiliated withMemorial Sloan Kettering Cancer Center Medical Institute

Research Area

Biography

Charles L. Sawyers has not added Biography.
If you are Charles L. Sawyers and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 2	Year
Publication title Cited by 17	2011
Publication title Cited by 21	2019

Other Publications

Article	Year
TORward AKTually useful mouse models. Nature medicine\| PubMed ID: 15170198	2004
Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (New York, N.Y.)\| PubMed ID: 15256671	2004
Rational therapeutic intervention in cancer: kinases as drug targets. Current opinion in genetics & development\| PubMed ID: 11790564	2002
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood\| PubMed ID: 11877262	2002
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Molecular and cellular biology\| PubMed ID: 11909978	2002
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood\| PubMed ID: 11986204	2002
Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood\| PubMed ID: 11986238	2002
Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Current opinion in hematology\| PubMed ID: 12042704	2002
Overview: the art of cancer drug screening: molecular target versus milieu-based screens. Current opinion in investigational drugs (London, England : 2000)\| PubMed ID: 12054100	2002
Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics. Cancer cell\| PubMed ID: 12086882	2002
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood\| PubMed ID: 12091333	2002
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nature reviews. Cancer\| PubMed ID: 12094235	2002
TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene\| PubMed ID: 12101412	2002
Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. Cancer cell\| PubMed ID: 12124170	2002
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 12149456	2002
Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nature genetics\| PubMed ID: 12161751	2002
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood\| PubMed ID: 12200353	2002
Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 12202652	2002
Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes, chromosomes & cancer\| PubMed ID: 12203791	2002
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer cell\| PubMed ID: 12204532	2002
The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics\| PubMed ID: 12223047	2002
Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer research\| PubMed ID: 12234993	2002
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood\| PubMed ID: 12351420	2002
Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. European journal of nuclear medicine and molecular imaging\| PubMed ID: 12418463	2002
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood\| PubMed ID: 12576334	2003
MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts. The Prostate\| PubMed ID: 12640659	2003
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 12684394	2003
Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer research\| PubMed ID: 12782577	2003
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer cell\| PubMed ID: 14522256	2003
AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. The Journal of biological chemistry\| PubMed ID: 14576155	2004
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene\| PubMed ID: 14576846	2003
Will mTOR inhibitors make it as cancer drugs? Cancer cell\| PubMed ID: 14667501	2003
Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes & development\| PubMed ID: 14701871	2003
Molecular determinants of resistance to antiandrogen therapy. Nature medicine\| PubMed ID: 14702632	2004
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 14990650	2004
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. The New England journal of medicine\| PubMed ID: 15306667	2004
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood\| PubMed ID: 15345592	2005
HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer cell\| PubMed ID: 15542435	2004
Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 15623612	2004
Cross-species comparisons of cancer signaling. Nature genetics\| PubMed ID: 15624012	2005
Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine\| PubMed ID: 15632041	2005
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 15705718	2005
Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature\| PubMed ID: 15829968	2005
Dynamics of chronic myeloid leukaemia. Nature\| PubMed ID: 15988530	2005
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 16046538	2005
Calculated resistance in cancer. Nature medicine\| PubMed ID: 16079872	2005
Amplification and overexpression of prosaposin in prostate cancer. Genes, chromosomes & cancer\| PubMed ID: 16080200	2005
Update on the use of imatinib mesylate. Clinical advances in hematology & oncology : H&O\| PubMed ID: 16258483	2005
Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 16278481	2005
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. The New England journal of medicine\| PubMed ID: 16282176	2005
Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nature medicine\| PubMed ID: 16341243	2006
Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer research\| PubMed ID: 16357166	2005
Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer research\| PubMed ID: 16424036	2006
Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 16492776	2006
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. The New England journal of medicine\| PubMed ID: 16775234	2006
Will kinase inhibitors have a dark side? The New England journal of medicine\| PubMed ID: 16855275	2006
Treating imatinib-resistant leukemia: the next generation targeted therapies. TheScientificWorldJournal\| PubMed ID: 16906325	2006
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer research\| PubMed ID: 16912159	2006
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 17164333	2006
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS medicine\| PubMed ID: 17177598	2006
Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer cell\| PubMed ID: 17560336	2007
Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer research\| PubMed ID: 17616663	2007
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. The Journal of clinical investigation\| PubMed ID: 17710227	2007
Where lies the blame for resistance--tumor or host? Nature medicine\| PubMed ID: 17917659	2007
Cancer: mixing cocktails. Nature\| PubMed ID: 17960228	2007
Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancer. Cancer research\| PubMed ID: 18045966	2007
Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS medicine\| PubMed ID: 18215105	2008
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Molecular cancer therapeutics\| PubMed ID: 18245668	2008
Something lost--something gained: the ASCI begins its second century. The Journal of clinical investigation\| PubMed ID: 18382722	2008
The cancer biomarker problem. Nature\| PubMed ID: 18385728	2008
Targeting the androgen receptor pathway in prostate cancer. Current opinion in pharmacology\| PubMed ID: 18674639	2008
A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer cell\| PubMed ID: 18691549	2008
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer research\| PubMed ID: 18701501	2008
Translational research: are we on the right track? 2008 American Society for Clinical Investigation Presidential Address. The Journal of clinical investigation\| PubMed ID: 18982165	2008
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer cell\| PubMed ID: 19061839	2008
Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. The Prostate\| PubMed ID: 19142959	2009
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer research\| PubMed ID: 19176386	2009
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (New York, N.Y.)\| PubMed ID: 19359544	2009
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nature genetics\| PubMed ID: 19396167	2009
Finding and drugging the vulnerabilities of RAS-dependent cancers. Cell\| PubMed ID: 19490885	2009
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer cell\| PubMed ID: 19573811	2009
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leukemia research\| PubMed ID: 19804904	2010
Shifting paradigms: the seeds of oncogene addiction. Nature medicine\| PubMed ID: 19812578	2009
Lessons learned from the development of kinase inhibitors. Clinical advances in hematology & oncology : H&O\| PubMed ID: 20020670	2009
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). Journal of medicinal chemistry\| PubMed ID: 20218717	2010
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet\| PubMed ID: 20398925	2010
Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. Cancer cell\| PubMed ID: 20478521	2010
Even better kinase inhibitors for chronic myeloid leukemia. The New England journal of medicine\| PubMed ID: 20525994	2010
Integrative genomic profiling of human prostate cancer. Cancer cell\| PubMed ID: 20579941	2010
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 20823238	2010
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature\| PubMed ID: 20927104	2010
Drug discovery: How melanomas bypass new therapy. Nature\| PubMed ID: 21164474	2010
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 21233402	2011
MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PloS one\| PubMed ID: 21394210	2011
FAS and NF-ÎºB signalling modulate dependence of lung cancers on mutant EGFR. Nature\| PubMed ID: 21430781	2011
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer cell\| PubMed ID: 21575859	2011
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 21606347	2011
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Science translational medicine\| PubMed ID: 21632985	2011
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. European urology\| PubMed ID: 21802835	2011
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PloS one\| PubMed ID: 22140458	2011
ARN-509: a novel anti-androgen for prostate cancer treatment. Cancer research\| PubMed ID: 22266222	2012